2313:HKEXShenzhou International Group Holdings Limited Analysis
Data as of 2026-03-11 - not real-time
HK$55.65
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Shenzhou International (2313.HK) is trading just above a key support around HK$55, with the 20‑day SMA (≈61.6) still above price and the 200‑day SMA (≈61.2) providing a neutral long‑term anchor. The RSI sits near 32, suggesting the stock is in oversold territory, while the MACD histogram is negative, indicating bearish momentum. Volume has been increasing, which may support a short‑term bounce, yet the overall trend is classified as neutral and market sentiment is in the "Extreme Greed" zone, hinting at potential over‑enthusiasm.
Fundamentally, the company delivers solid revenue growth of roughly 15% YoY, healthy operating margins (~19%) and a robust cash position that dwarfs its debt. The dividend yield is attractive at about 4.8% with a payout ratio near 53%, and free cash flow remains positive. However, the discounted cash‑flow model values the shares near HK$34, well below the current price of HK$55, implying the stock is overvalued relative to intrinsic estimates despite a strong earnings outlook.
Fundamentally, the company delivers solid revenue growth of roughly 15% YoY, healthy operating margins (~19%) and a robust cash position that dwarfs its debt. The dividend yield is attractive at about 4.8% with a payout ratio near 53%, and free cash flow remains positive. However, the discounted cash‑flow model values the shares near HK$34, well below the current price of HK$55, implying the stock is overvalued relative to intrinsic estimates despite a strong earnings outlook.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Price near technical support with rising volume
- Oversold RSI indicating potential rebound
- High dividend yield offering immediate income
Medium Term
1–3 yearsNeutral
Model confidence: 8/10
Key Factors
- Steady revenue growth and solid margins
- Strong cash generation supporting dividend sustainability
- Valuation still above DCF fair value, limiting upside
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Low beta and defensive cash‑rich balance sheet
- Consistent dividend policy
- Overvaluation relative to intrinsic value suggests limited long‑run price appreciation
Key Metrics & Analysis
Financial Health
Revenue Growth15.30%
Profit Margin21.16%
P/E Ratio11.4
ROE18.25%
ROA7.10%
Debt/Equity40.04
P/B Ratio2.0
Op. Cash FlowHK$5.7B
Free Cash FlowHK$1.5B
Technical Analysis
TrendNeutral
RSI32.1
SupportHK$55.30
ResistanceHK$66.30
MA 20HK$61.64
MA 50HK$62.09
MA 200HK$61.16
MACDBearish
VolumeIncreasing
Fear & Greed Index76.23
Valuation
Fair ValueHK$34.42
Target PriceHK$80.95
Upside/Downside45.46%
GradeOvervalued
TypeBlend
Dividend Yield4.78%
Risk Assessment
Beta0.29
Volatility34.72%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.